Parker Waichman LLP Headlines by Topic
Raptiva
Raptiva No Longer Available in Canada
Jun 18, 2009
| Parker Waichman LLP
Raptiva has been pulled from the market in Canada because of its association with an often-fatal brain infection called progressive multifocal...
Raptiva Pulled from U.S. Market Following PML Deaths
Apr 8, 2009
| Parker Waichman LLP
Raptiva, an injectable drug used to treat moderate to severe plaque psoriasis, is being withdrawn from the U.S. market. According to...
Raptiva Sales Suspension Recommended in Europe After Reports of Brain Infections
Feb 20, 2009
| Parker Waichman LLP
On the same day U.S. regulators warned that the psoriasis drug Raptiva had been linked to three fatal case of a rare brain infection, their...
Raptiva Linked to Deadly Brain Disease
Feb 19, 2009
| Parker Waichman LLP
U.S. health regulators warned today that the psoriasis drug Raptiva has been associated with three fatal cases of a brain infection known as...
Raptiva Gets Black Box Warning for PML, Other Opportunistic Infections
Oct 17, 2008
| Parker Waichman LLP
The labeling of the psoriasis drug Raptiva will now bear a new black box warning about its association with the deadly brain disease...
Raptiva Added to List of Drugs Linked to Deadly Brain Disease
Oct 6, 2008
| Parker Waichman LLPp
Raptiva, Genentech Inc’s psoriasis drug, may be linked to a deadly brain disease called progressive multifocal leukoencephalopathy, or...
Reports of Severe Anemia, Infections, and Rare Blood Disease Prompt New Safety Warning for Psoriasis Drug Raptiva
Jul 21, 2005
| www.newsinferno.com
The FDA and Genetech have issued a new safety warning for the psoriasis drug Raptiva which addresses serious potential side effects of the drug...
Page 1/1
